Search

Filters

Clear All
  • 12
  • 44
  • 538

Phase

  • 9
  • 14
  • 49
  • 8
  • 66
  • 3
  • 439
  • 519
  • 256
  • 591
  • 3

Found 594 results for IU Health Enterprise System

A listing of IU Health Enterprise System medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

A Multi-Center, Prospective, Longitudinal, Study Evaluating Immunologic, Inflammatory, and Laboratory Parameters Associated With Long-Term Palynziq® (Pegvaliase) Treatment in Subjects With Phenylketonuria (PKU) in the United States

M
Melissa Lah, MD
All genders
Observational
This is a 10-year multi-center, prospective, longitudinal, single arm study evaluating immunologic, inflammatory and laboratory parameters associated with long-term Palynziq treatment in subjects with phenylketonuria (PKU) in the United States (US). Subjects in the US for whom a clinical decision has been made that they will receive pegvaliase to treat …

A Randomized Phase 3 Trial of Fludarabine/Cytarabine/Gemtuzumab Ozogamicin With or Without Venetoclax in Children With Relapsed AML

S
Sandeep Batra, MD
29 days - 21 years
All genders
Phase 3
A study to evaluate if the randomized addition of venetoclax to a chemotherapy backbone (fludarabine/cytarabine/gemtuzumab ozogamicin [GO]) improves survival of children/adolescents/young adults with acute myeloid leukemia (AML) in 1st relapse who are unable to receive additional anthracyclines, or in 2nd relapse.THIS STUDY IS ENROLLING BY INVITATION ONLY - Consistent with …

A Randomized, Double-Blind, Placebo-Controlled, Phase 2b Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Patients With Graves' Disease

C
Cary Mariash, MD
18 years - 75 years
All genders
Phase 2/3
Interventional
This is a study to assess the efficacy, safety, and tolerability of IMVT-1402 in adult participants with Graves' disease (GD) who are hyperthyroid despite antithyroid drug (ATD) treatment.The primary objective of this study is to evaluate the efficacy of IMVT-1402 versus placebo as assessed by T3 (total triiodothyronine [T3] or …

Long-term Characterization of GORE® TAG® Conformable Thoracic Stent Graft With ACTIVE CONTROL System Performance

J
Joel Corvera, MD
18 years - 100 years
All genders
Observational
An observational, prospective multi-regional post-market registry collecting mid- and long-term data to assess outcomes through ten years of follow-up for subjects treated with GORE® TAG® Conformable Thoracic Stent Graft with ACTIVE CONTROL System as a part of routine clinical practice. This post-market registry for the GORE® TAG® Conformable Thoracic Stent …

Global Prospective Hemolytic Disease of the Fetus and Newborn Registry

H
Hiba Mustafa, MD
All genders
The purpose of the study is to prospectively evaluate treatment effectiveness and outcomes for alloimmunized pregnant participants and their corresponding fetuses, neonates, infants, and children at risk for HDFN in a real-world setting. This prospective registry enables the identification of risk factors, disease progression patterns, and treatment outcomes in ways …

Risk Adapted Treatment of Unilateral Favorable Histology Wilms Tumors (FHWT)

M
Marissa Just
All genders
Phase 3
This phase III trial studies using risk factors in determining treatment for children with favorable tissue (histology) Wilms tumors (FHWT). Wilms Tumor is the most common type of kidney cancer in children, and FHWT is the most common subtype. Previous large clinical trials have established treatment plans that are likely …

A Post-Authorization Safety Study (Pass) to Assess Long-Term Safety in Patients with Pompe Disease Treated with Avalglucosidase Alfa in the Real-World Setting: the Savant (Safety Assessment of Avalglucosidase Alfa as a Novel Treatment) Study

M
Melissa Lah, MD
18 years - 100 years
All genders
Observational
This is an observational study with the aim of gathering safety information on avalglucosidase alfa treatment for Pompe disease. We will collect long term safety data and evaluate the important identified risk of infusion associated reactions (IARs) including hypersensitivity and anaphylactic reactions and the important potential risk of medication errors …

A Phase 3, Double-Blind, Placebo-Controlled, Randomized Study to Assess the Safety of Epicutaneous Immunotherapy With Dbv712 250 Mcg in 1-Through 3-Year-Old Children With Peanut Allergy

G
Girish Vitalpur, MD
1 years - 3 years
All genders
Phase 3
Interventional
The primary objective of this study is to assess the 6-month safety of DBV712 250 micrograms (mcg) in subjects 1 through 3 years of age with peanut allergy.THIS STUDY IS ENROLLING BY INVITATION ONLY

Evaluation of the Effect of Acute Kidney Injury on Body Composition Among Preterm Infants. A Prospective Case-Control Observational Pilot Study

B
Brianna Liberio
All genders
Interventional
The purpose of this study is to assess the body composition and growth measurements at time of NICU discharge of preterm infants who experienced acute kidney injury during their hospitalization, and to compare this with matched controls who did not experience acute kidney injury.THIS STUDY IS ENROLLING BY INVITATION ONLY …

Ketamine Add-On Therapy for Established Status Epilepticus Treatment Trial

P
Paul Musey, MD
All genders
Interventional
The goal of this clinical trial is to determine if treatment of patients with two doses of ketamine plus levetiracetam versus levetiracetam alone leads to more effective control of status epilepticus.THIS STUDY IS ENROLLING BY INVITATION ONLY
341 - 350 of 594